FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.
作者信息
Chen Jianmin, Lu Weihong, Zhang Yi, Fan Weixing, Tang Wei, Zhang Chen
机构信息
Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.
Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
Asian J Psychiatr. 2020 Dec;54:102352. doi: 10.1016/j.ajp.2020.102352. Epub 2020 Aug 7.
In this study, we hypothesized that fatty acid desaturase-1 (FADS1) and fatty acid desaturase-2 (FADS2) may mediate metabolic syndrome (MetS) in patients receiving olanzapine monotherapy. 216 schizophrenia patients were recruited. There is a significant difference between the patients with or without MetS in term of the expression of FADS1 mRNA (F = 4.58, P = 0.03), but not FADS2 mRNA (F = 1.29, P = 0.26). We observed a positive association between FADS1 mRNA and high-density lipoprotein cholesterol (P = 0.04), and a negative association between FADS1 mRNA and systolic blood pressure (P = 0.04). Our findings implied that FADS1 may be an important genetic modifier that can regulate olanzapine-associated metabolic disturbance.
Zotero 插件